Bethell G, Wilkinson D, Fawkner-Corbett D, Mesa A, Shukla R, Edgar D, Kenny S (2016)
Enteric nervous system stem cells associated with thickened extrinsic fibers in short segment aganglionic Hirschsprung's disease gut are absent in the total colonic and intestinal variants of disease
J Pediatr Surg 51: 1581

Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D (2013)
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
Alzheimers Res Ther 5: 6

Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P (2012)
Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial
J Alzheimers Dis 29: 459

Wilkinson D (2012)
A review of the effects of memantine on clinical progression in Alzheimer's disease
Int J Geriatr Psychiatry 27: 769

Thompson HM, Wilkins S, Battersby AH, Waite RJ, Wilkinson D (2007)
Modelling long-term effects of IGRs on honey bee colonies
Pest Manag Sci 63: 1081

Burns A, O'Brien J, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D (2006)
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
J Psychopharmacol 20: 732

Thompson HM, Wilkins S, Battersby AH, Waite RJ, Wilkinson D (2005)
The effects of four insect growth-regulating (IGR) insecticides on honeybee (Apis mellifera L.) colony development, queen rearing and drone sperm production
Ecotoxicology 14: 757

Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D (2004)
AD2000: design and conclusions
Lancet 364: 1213

Jackson S, Ham RJ, Wilkinson D (2004)
The safety and tolerability of donepezil in patients with Alzheimer's disease
British Journal of Clinical Pharmacology 58 Suppl 1: 1

Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, Butler S, Wilkinson D, Woolford J, Waite J, McKeith IG (2001)
Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial
Int Psychogeriatr 13: 199

Wilkinson D, Murray J (2001)
Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease
Int J Geriatr Psychiatry 16: 852

Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D (2001)
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
Int J Geriatr Psychiatry 16: 653

McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK (2000)
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial
Int J Geriatr Psychiatry 15: 387

Shikiar R, Shakespeare A, Sagnier PP, Wilkinson D, McKeith I, Dartigues JF, Dubois B (2000)
The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial
J Am Geriatr Soc 48: 268

Wilkinson D (1998)
Clinical experience with Donepezil (Aricept) in the UK
J Neural Transm Suppl 54: 311

Wilkinson D (1997)
Advertisements for donepezil. Review of drug in Drug and Therapeutics Bulletin is uninformed
BMJ 315: 1625